TY - CHAP AU - Payne, R. AU - Glenn, L. AU - Hoen, H. AU - Richards, B. AU - Smith, J. W. AU - Lufkin, R. AU - Crocenzi, T. S. AU - Urba, W. J. AU - Curti, B. D. PY - 2014 DA - 2014// BT - Durable responses and reversibile toxicity of high-dose interleukin 2 treatment of melanoma and renal cancer in a community hospital biotherapy program ID - Payne2014 ER - TY - JOUR AU - Merriman, J. PY - 2014 DA - 2014// TI - Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). ASCO 2014 JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.49.4757 DO - 10.1200/JCO.2013.49.4757 ID - Merriman2014 ER - TY - JOUR AU - Morse, M. PY - 2014 DA - 2014// TI - High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). ASCO 2014 JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.49.4757 DO - 10.1200/JCO.2013.49.4757 ID - Morse2014 ER - TY - JOUR AU - Daniels, G. PY - 2014 DA - 2014// TI - Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. ASCO 2014 JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.49.4757 DO - 10.1200/JCO.2013.49.4757 ID - Daniels2014 ER - TY - STD TI - Hughes T, Iodice G, Basu S, Fung H, Maciejewski J, Nathan S, Rich E, Bines S, Kaufman H et al.: Clinical Benefit of High Dose IL-2 (HD IL-2) Therapy Depends on the Kinetics of Response: Evidence for Improved Overall Survival in Patients with Stable Disease. (submitted to Cancer Immunology Immunotherapy) ID - ref5 ER - TY - JOUR AU - Kaufman, H. L. AU - Wong, K. K. AU - Daniels, G. A. AU - McDermott, D. F. AU - Aung, S. AU - Lowder, J. N. AU - Morse, M. A. PY - 2014 DA - 2014// TI - The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2) JO - Journal of Personalized Medicine VL - 4 UR - https://doi.org/10.3390/jpm4010052 DO - 10.3390/jpm4010052 ID - Kaufman2014 ER -